<?xml version="1.0" encoding="UTF-8"?>
<ref id="b44-1030717">
 <label>44.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Nishimoto</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Terao</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Mima</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Nakahara</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Takagi</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Kakehi</surname>
    <given-names>T</given-names>
   </name>
  </person-group>
  <article-title>Mechanisms and pathologic significances in increase in serum interleukin 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6-receptor antibody, tocilizumab, in patients with rheumatoid arthritis</article-title>. 
  <source>Blood</source>. 
  <year>2008</year>;
  <volume>112</volume>(
  <issue>10</issue>):
  <fpage>3959</fpage>â€“
  <lpage>3964</lpage>.
  <pub-id pub-id-type="pmid">18784373</pub-id>
 </mixed-citation>
</ref>
